What is Gilead Sciences'(gild) stock symbol?
What is Gilead Sciences' stock symbol? Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD." Who are Gilead Sciences' major shareholders?
What is the price targets for Gilead Sciences'stock?
Their forecasts range from $60.00 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $79.32 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Gilead Sciences.
What is Gilead Sciences's PE (price/earnings) ratio?
The P/E ratio of Gilead Sciences is 11.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 18.60. Gilead Sciences has a PEG Ratio of 0.72.
Where can I buy shares of gild?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
See more
Is GILD stock a good buy?
Out of 12 analysts, 2 (16.67%) are recommending GILD as a Strong Buy, 2 (16.67%) are recommending GILD as a Buy, 7 (58.33%) are recommending GILD as a Hold, 0 (0%) are recommending GILD as a Sell, and 1 (8.33%) are recommending GILD as a Strong Sell.
Is Gilead a public company?
Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500....Gilead Sciences.TypePublicTotal equityUS$21.06 billion (2021)Number of employees14,400 (2021)12 more rows
Who owns Gileads stock?
Top 10 Owners of Gilead Sciences IncStockholderStakeShares ownedThe Vanguard Group, Inc.8.01%100,472,614BlackRock Fund Advisors6.55%82,203,205SSgA Funds Management, Inc.4.62%57,970,959Capital Research & Management Co....4.46%55,951,3796 more rows
Why is Gilead stock so low?
Gilead Sciences (GILD) said Tuesday its Covid treatment dragged on fourth-quarter sales as two legal charges hammered earnings — and GILD stock tumbled. During the December quarter, sales of the Covid treatment called Veklury sank 30% to roughly $1.36 billion.
Is Gilead a Fortune 500 company?
Gilead Sciences – With a new chief executive officer and leadership team in place this year, Gilead Sciences is undergoing a transformation as it diversifies and bolsters its portfolio. This year, the company placed at 139 on the Fortune 500 list with revenue of $22.1 billion.
Does Gilead Sciences pay a dividend?
GILD pays a dividend of $0.73 per share. GILD's annual dividend yield is 4.59%. When is Gilead Sciences ex-dividend date? Gilead Sciences's previous ex-dividend date was on Jun 13, 2022.
What products does Gilead make?
MedicinesHIV / AIDS. Liver Diseases. Hematology / Oncology. ... COVID-19. Veklury® (remdesivir) 100 mg for injection. ... Liver Disease. Epclusa® sofosbuvir 400 mg/velpatasvir 100 mg. ... Hematology/Oncology/Cell Therapy. Tecartus™ ... Cardiovascular. Letairis® ... Inflammation/Respiratory. Cayston® ... Other Medicines. AmBisome®
What country is Gilead in?
Gilead, area of ancient Palestine east of the Jordan River, corresponding to modern northwestern Jordan. The region is bounded in the north by the Yarmūk River and in the southwest by what were known in ancient times as the “plains of Moab”; to the east there is no definite boundary.
Should I buy or sell Gilead Sciences stock right now?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rat...
What is Gilead Sciences' stock price forecast for 2022?
14 analysts have issued 1 year target prices for Gilead Sciences' stock. Their forecasts range from $56.00 to $90.00. On average, they anticipate G...
How has Gilead Sciences' stock price performed in 2022?
Gilead Sciences' stock was trading at $72.61 at the start of the year. Since then, GILD shares have decreased by 16.3% and is now trading at $60.74...
When is Gilead Sciences' next earnings date?
Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Gile...
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings results on Thursday, April, 28th. The biopharmaceutical company reported $2.12 ea...
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences declared a quarterly dividend on Monday, May 2nd. Shareholders of record on Wednesday, June 15th will be given a dividend of $0.73...
Is Gilead Sciences a good dividend stock?
Gilead Sciences(NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.77%. GILD has a dividend yield high...
What guidance has Gilead Sciences issued on next quarter's earnings?
Gilead Sciences issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $6...
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the following people: Mr. Daniel P. O'Day , Chairman & CEO (Age 58, Pay $6.09M) Mr. Andrew D. Dickinso...
How much does Gilead make?
When will Gilead Sciences release its earnings?
Gilead Sciences has a market capitalization of $85.30 billion and generates $24.69 billion in revenue each year. The biopharmaceutical company earns $123 million in net income (profit) each year or $7.09 on an earnings per share basis.
What is the dividend payout ratio for Gilead Sciences?
Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021. View our earnings forecast for Gilead Sciences.
Where is Gilead headquartered?
Gilead Sciences does not yet have a strong track record of dividend growth. The dividend payout ratio of Gilead Sciences is 40.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 41.64% next year.
What is Gilead Sciences?
1.36B. 40.45%. About. . Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
What is Gilead Sciences?
. . Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Does market cap include convertible securities?
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C . The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination dru
Daily Spotlight: Values in Healthcare, Financial, Tech
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
Market Digest: GILD, GPS, JBLU, LRCX, NUE, STX, RTX, MA, CFG
Investors hunting for stocks that reasonably balance long-term growth prospects and current value characteristics might want to look at companies in the Financial Services, Information Technology, and Healthcare sectors. These are among the groups that are selling for (price/earnings)/ (growth+yield) ratios at or below the S&P 500's ratio of 2.2x.
Large Cap US Pick List - November 2021
Stocks gave up strong early gains on Thursday, ending in the red after initially rallying on much better-than-expected economic data. The Commerce Department said that the U.S. economy expanded at a 6.9% rate in 4Q, up strongly from the prior quarter and well above the consensus forecast.
Large Cap US Pick List - October 2021
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Large Cap US Pick List - September 2021
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Large Cap US Pick List - August 2021
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Large Cap US Pick List - July 2021
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Recently Viewed Tickers
This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.
Gilead Sciences Inc
Visit a quote page and your recently viewed tickers will be displayed here.
